EP2571499A1 - Pharmazeutische zusammensetzung mit einem n- acetylcystein und einem xanthin - Google Patents

Pharmazeutische zusammensetzung mit einem n- acetylcystein und einem xanthin

Info

Publication number
EP2571499A1
EP2571499A1 EP11729783A EP11729783A EP2571499A1 EP 2571499 A1 EP2571499 A1 EP 2571499A1 EP 11729783 A EP11729783 A EP 11729783A EP 11729783 A EP11729783 A EP 11729783A EP 2571499 A1 EP2571499 A1 EP 2571499A1
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
composition according
sodium
calcium
starch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11729783A
Other languages
English (en)
French (fr)
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2571499A1 publication Critical patent/EP2571499A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Definitions

  • Doxophylline is a methylxanthine compound which is known with its bronchial and antitussive activity. In addition, it is effective in indications of bronchospasm, obstructive chronic bronchitis and spasmodic cough.
  • the inventors have surprisingly obtained a more advantageous mucolytic effect by combining NAC and xanthine derivative compounds and found that the treatment in which the combination of the present invention is administered induces greater therapeutic benefit in comparison with the treatment in which said active ingredients are administered separately.
  • the inventors have found the use of xanthine derivative compounds in combination with N-Acetylcysteine that is a mucolytic agent both for the treatment of said diseases; expectoration and reduction of phlegm caused by these diseases and easing expectoration provides positive therapeutic effect.
  • the active agent NAC in the composition pertaining to the present invention is preferably in doses of 200, 600, 900, 1200 mg and xanthine derivative compounds are preferably in doses of 200, 400 mg.
  • Stabilizing agent/agents can be selected from chelating agents and alkalinizing agents.
  • Chelating agents can be selected from the group comprising disodium EDTA, edetic acid, citric acid, sodium citrate, potassium citrate or combinations thereof.
  • Alkalinizing agents can be selected from alkali metal salts such as sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, sodium silicate, disodium hydrogen orthophosphate, sodium aluminate; alkaline earth metal salts such as calcium carbonate, calcium hydroxide, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulphate, calcium acetate, calcium gluconate, calcium glycerophosphate, magnesium carbonate, magnesium hydroxide, magnesium sulphate, magnesium acetate, magnesium silicate, magnesium aluminate; and organic compounds such as primary, secondary and tertiary amines, cyclic amines, ⁇ , ⁇ '- dibenzylethylenediamine, diethanolamine, ethylenediamine, meglumine, monosodium glutamate, polacryline sodium, sodium alginate.
  • alkali metal salts such as sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, sodium silicate, disodium hydrogen orthophosphate, sodium alumina
EP11729783A 2010-05-18 2011-05-16 Pharmazeutische zusammensetzung mit einem n- acetylcystein und einem xanthin Withdrawn EP2571499A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201003538 2010-05-18
PCT/TR2011/000110 WO2011146031A1 (en) 2010-05-18 2011-05-16 Pharmaceutical composition comprising n- acetylcysteine and a xanthine

Publications (1)

Publication Number Publication Date
EP2571499A1 true EP2571499A1 (de) 2013-03-27

Family

ID=44316849

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11729783A Withdrawn EP2571499A1 (de) 2010-05-18 2011-05-16 Pharmazeutische zusammensetzung mit einem n- acetylcystein und einem xanthin

Country Status (2)

Country Link
EP (1) EP2571499A1 (de)
WO (1) WO2011146031A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201014391D0 (en) * 2010-08-27 2010-10-13 Biocopea Ltd Drug composition and its use in therapy
GB201107176D0 (en) * 2011-04-28 2011-06-15 Cxr Biosciences Ltd Pyrrolnitrin derivatives
TR201104738A2 (tr) * 2011-05-16 2012-12-21 Bi̇lgi̇ç Mahmut N-Asetilsistein içeren farmasötik kombinasyon.
EP2945616B1 (de) * 2013-01-15 2018-11-28 NuSirt Sciences, Inc. Behandlung von lungenerkrankungen
FR3047898B1 (fr) * 2016-02-23 2020-09-18 Alpex Pharma Granules non effervescents contenant de la n-acetylcysteine.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3184505A (en) 1962-06-18 1965-05-18 Mead Johnson & Co Process for the n-monoacylation of cysteine
IT1113122B (it) 1978-04-06 1986-01-20 Abc Ist Biolog Chem Spa Composizione farmaceutica ad attivita' antibrocospastica e antitosse
DE2842822C3 (de) * 1978-09-30 1982-05-19 Merz + Co GmbH & Co, 6000 Frankfurt Arzneistoffzubereitungen schwerlöslicher Arzneistoffe in Form von Brausegranulaten
CH667590A5 (it) * 1986-07-24 1988-10-31 Inpharzam Int Sa Composizione farmaceutica effervescente idrosolubile contenente n-acetil-cisteina. .
EP1869207A1 (de) * 2005-04-07 2007-12-26 AstraZeneca AB Verfahren zur beurteilung der veranlagung zu und/oder anfälligkeit für copd mittels fgf-bpi-analyse
CA2704100C (en) * 2007-10-26 2017-07-04 Pacific Therapeutics Ltd. Compositions and methods for treating fibroproliferative disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2011146031A1 *

Also Published As

Publication number Publication date
WO2011146031A1 (en) 2011-11-24

Similar Documents

Publication Publication Date Title
ES2680638T3 (es) Gránulos efervescentes de ácido gamma-hidroxibutírico
EP2490676B1 (de) Pharmazeutische zusammensetzung eines pde-5 inhibitors und dapoxetin
US10441585B2 (en) Formulations containing nalbuphine and uses thereof
KR102197429B1 (ko) 심혈관 질환의 치료를 위한 약학 조성물 및 방법
EP2571499A1 (de) Pharmazeutische zusammensetzung mit einem n- acetylcystein und einem xanthin
EP2393478B1 (de) Pharmazeutische zusammensetzung mit hoher bioverfügbarkeit und maskiertem geschmack und geruch
KR102239291B1 (ko) 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
WO2014027981A2 (en) Effervescent tablet formulations of dapoxetine and a pde5 inhibitor
EP2563340A2 (de) Wasserlösliche pharmazeutische zusammensetzung
WO2010090612A1 (en) Stable, taste and odor masked pharmaceutical compositions comprising acetylcystein and vitamin c
EP2566449B1 (de) Pharmazeutische zusammensetzungen mit ceftibuten
JP4377564B2 (ja) 内服用組成物
US9717692B2 (en) Effervescent formulations comprising dexketoprofen
WO2019203753A2 (en) The pharmaceutical combination comprising dapoxetine, phosphodiesterase type-5 inhibitor and anti-emetic agent
WO2011093831A2 (en) Effervescent formulations comprising cefprozil as active agent
KR101633292B1 (ko) 용법이 개선된 엔테카비어를 함유하는 약학적 조성물
WO2013055302A1 (en) Effervescent composition comprising n- acetylcysteine and doxophylline or theophylline
US20180140570A1 (en) Product based on iron bis-glycinate chelate and alginic acid and/or water-soluble salts thereof, formulations thereof, and pharmaceutical uses thereof
EP2959889A1 (de) Im mund zerfallende formulierungen von loxoprofen
EP2962684A1 (de) Im mund zerfallende formulierungen von tadalafil
WO2019074464A2 (en) PHARMACEUTICAL COMBINATION COMPRISING DAPOXETINE AND PHOSPHODIESTERASE TYPE 5
WO2012039691A2 (en) Synergic effect
US20120149720A1 (en) Valacyclovir formulations
WO2014035355A1 (en) Pharmaceutical combination comprising idebenone and memantine
WO2016001143A1 (en) Orally disintegrating formulations of tadalafil

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20121129

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20131021

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160212